Risk of thrombosis in association with oral contraceptive use from hematologist΄s point of view

Czech version

Authors: Petr Dulíček ¹; Eva Ivanová ¹; Petr Sadílek ¹; Martin Beránek ²
Authors‘ workplace: IV. interní hematologická klinika, LF UK a FN, Hradec Králové ¹; Ústav klinické biochemie a diagnostiky, LF UK a FN, Hradec Králové ²
Published in: Prakt Gyn 2013; 17(4): 277-282
Category: Gynecology and Obstetrics: Review Article

Trombotické komplikace jsou více než 50 let dobře známou komplikací užívání hormonální antikoncepce. Riziko je jak pro trombózu žilní, tak arteriální. Příčiny trombóz jsou velmi často multifaktoriální a závisí na celé řadě dalších rizikových faktorů. V článku se zabýváme zejména rizikovostí vrozených trombofilních stavů, a to především mutací FV Leiden a mutací FII 20210a. Hormonální antikoncepce patří mezi časté příčiny trombózy u žen v produktivním věku, nicméně správným zhodnocením všech dalších rizikových faktorů a zajištěním všech rizikových situací je možné toto riziko snížit.

Overview

Thrombotic diathesis is more than 50 years well known complication of oral contraceptive use. The risk is not only for venous thrombosis, but also for arterial one. Etiology is usually a multifactorial and depends on a several additional risk factors. We discuss the role of inherited thrombophilia with the focus on F V Leiden mutation and FII20210a mutation. Hormonal contraception use belongs among very frequent causes of thrombosis in female in reproductive age. However, this risk is possible to decrease after appropriate assessment of all additional risk factors and due to thromboprophylaxis in risk situations.

Key words:
hormonal contraceptive pill – thrombophilia – venous thromboembolism

Sources

1. Nordström M, Lindblad B, Bergqvist D et al. A prospective study of the incidence of deep – vein thrombosis within a defined urban population. J Intern Med 1992; 232(2): 155–160.

2. Middeldorp S, Meijers JCM, van den Ende AE et al. Effects on coagulation of levonorgestrel and desogestrel containing low dose oral contraceptives: a cross over study. Thromb Haemost 2000; 84(1): 4–8.

3. Jordan WM, Anand JK. Pulmonary embolism. Lancet 1961; 278(7212): 1146–1147.

4. Meade TW, Greenberg G, Thompson SG.et al. Progestagens and cardiovascular reactions associated with oral contraceptives and comparison of the safety of 50- and 30-microgram oestrogen preparations. Br Med J 1980; 280(6224): 1157–1160.

5. Böttiger LE, Boman G, Eklund G et al. Oral contraceptives and thromboembolic disease: effects of lowering estrogen content. Lancet 1980; 1(8178): 1097–1101.

6. Gerstman BB, Piper JM, Tomita DK et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133(1): 32–37.

7. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contarception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346(8990): 1575–1582.

8. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Tromb Haemost 1997; 78(1): 1–6.

9. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and prgestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921. Dostupné z DOI: <http://doi: 10.1136/bmj.b2921>.

10. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160(1): 49–52.

11. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354(9173): 127–128.

12. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89(3): 493–498.

13. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323(7305): 131–134.

14. Battaglioni T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opion Hematol 2007; 14(5): 488–493.

15. Meijers JC, Middeldorp S, Tekelenburg W et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI – independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Tromb Haemost 2000; 84(1): 9–14.

16. Tans G, Curvers J, Middeldorp S et al. A randomised a cross over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84(1): 15–21.

17. Dinger JC, Heinemann LA, Kühl-Habich D et al. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptions based on 142,475 women-years of observation. Contraception 2007; 75(5): 344–354.

18. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J et al. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013; 27(1): 25–34.

19. Lidegaard Ø, Nielsen LH, Skovlund CW et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study. Denmark 2001–10. BMJ 2012; 344: e2990. Dostupné z DOI: <http://doi: http://dx.doi.org/10.1136/bmj.e2990>.

20. Lidegaard Ø, Løkkegaard E, Svendsen AL et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890. Dostupné z DOI: <http://doi: 10.1136/bmj.b2890>.

21. Lidegaard Ø, Nielsen LH, Skovlund CW et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011; 343: d6423. Dostupné z DOI: <http://doi: 10.1136/bmj.d6423>.

22. Vasilakis C, Jick H, del Mar Melero-Montes M.. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354(9190): 1610–1611.

23. Jick S, Kaye JA, Li L et al. Further results on the risk of nonfatal venous thromboembolism in users of zhe contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007; 76(1): 4–7.

24. Cole JA, Norman H, Doherty M et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109(2 Pt 1): 339–346.

25. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestagen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998; 57(5): 315–324.

26. van Hylckama Vlieg A, Hellmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30(11): 2297–2300.

27. Gemzell-Danielsson K, Inki P, Heikinheimo O. Safety and Efficacy of the Levonorgestrel-releasing Intrauterine System. Expert Rev Obstet Gynecol 2013; 8(3): 235–247.

28. van Hylckama Vlieg A., Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J Thrombo Haemost 2011; 9(2): 257–266.

29. Naess IA, Christiansen SC, Romundstad P et al. Incidence and mortality of venous thrombosis: a population – based study. J Thromb Haemost 2007; 5(4): 692–699.

30. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspektive of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151(5): 933–938.

31. Salden A, Keeney S, Hay CR et al. The C677T MTHFR variant and the risk of venous thrombosis. Br J Haematol 1997; 99(2): 472.

32. Tosetto A, Missiaglia E, Frezzato M et al. The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol 1997; 97(4): 804–806.

33. Brown K, Luddington R, Baglin T. Effect of the MTHFR C677T variant on the risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998; 103(1): 42–44.

34. Simioni P, Sanson BJ, Prandoni P et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81(2): 198–202.

35. Martinelli I, Mannucci PM, De Stefano V et al. Different risk of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92(7): 2353–2358.

36. Vandenbroucke JP, Koster T, Briët E et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344(8935): 1453–1457.

37. Rosendaal FR, Koster T, Vandenbroucke JP et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85(6): 1504–1508.

38. Rintelen C, Mannhalter C, Ireland H et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93(2): 487–490.

39. Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of factor F V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86(3): 809–816.

40. Dulíček P, Malý J, Pecka et al. Venous thromboembolism in young female while on oral contraceptives: high frequency of inherited thrombophilia and analysis of thrombotic events in 400 czech women. Clin Appl Thromb Hemost 2009; 15(5): 567–573.

41. Dulíček P, Sadílek P, Beránek M et al. Výskyt venózního tromboembolizmu u žen v časové souvislosti s užíváním hormonální antikoncepce. Transfuze hematol. dnes, 2013; 19(1): 33–38.

42. Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366(24): 2257–2266.